Giannicola Genovese, M.D., Ph.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Scientific Director TRACTION Platform, Department of Therapeutic Discovery, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor, Department of Genitourinary Medical Oncology-Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2014 | Catholic University of Sacred Heart, Rome, IT, Oncology and Cancer Biology, Ph.D |
| 2004 | University of Rome "La Sapienza", Rome, IT, Medicine, MD |
Postgraduate Training
| 2009-2011 | Visiting Fellowship, Genomic Medicine, Dana Farber Cancer Institute, Boston, Massachusetts |
| 2007-2009 | Visiting Fellowship, Medical Oncology, Columbia University/Herbert Irving Cancer Center, New York, New York |
| 2004-2004 | Internship, Pathology, Neurological Institute, Rome |
| 2004-2008 | Clinical Fellowship, Internal Medicine/Oncology, Catholic University of Rome, Rome |
| 2004-2004 | Internship, Pathology, University of Rome, Rome |
Experience & Service
Academic Appointments
Assistant Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - 2023
Instructor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2017
Instructor, Department of Medical Oncology, Dana Farber Cancer Institute/Harvard University, Boston, MA, 2011 - 2012
Other Appointments/Responsibilities
Consultantship, IRCSS-CROB, Clinical Consulatant, Rionero, 2017 - Present
Honors & Awards
| 2023 | Potu N. Rao Award for Excellence in Basic Science |
Professional Memberships
AACR
2007 - Present
Selected Publications
Peer-Reviewed Articles
- Lucchetti D, Colella F, d'Amati A, Servidei T, Gessi M, Parillo C, Cellini B, Toma F, Giaco L, Persiani F, Perelli L, Mantini G, Genovese G, Masetto I, Ruggiero A, Sgambato A. SPATIAL ANALYSIS IDENTIFIES CD147 AS A NOVEL MARKER OF HIGH-GRADE CHILDHOOD POSTERIOR FOSSA EPENDYMOMA. Lab Invest:104175, 2025. e-Pub 2025. PMID: 40250710.
- Grimm SL, Karki M, Blum KA, Bertocchio JP, He R, Tripathi DN, Zacharias NM, Lebenthal JM, Sheth RA, Rao P, Genovese G, Lu Z, Bast RC, Ingram DR, Lazcano R, Wani KM, Wang WL, Lazar AJ, Tannir NM, Walker CL, Coarfa C, Msaouel P. CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation. Clin Cancer Res 31(6):1057-1068, 2025. e-Pub 2025. PMID: 39836407.
- Perelli L, Zhang L, Mangiameli S, Giannese F, Mahadevan KK, Peng F, Citron F, Khan H, Le C, Gurreri E, Carbone F, Russell AJC, Soeung M, Lam TNA, Lundgren S, Marisetty S, Zhu C, Catania D, Mohamed AMT, Feng N, Augustine JJ, Sgambato A, Tortora G, Draetta GF, Tonon G, Futreal A, Giuliani V, Carugo A, Viale A, Kim MP, Heffernan TP, Wang L, Kalluri R, Cittaro D, Chen F, Genovese G. Evolutionary fingerprints of epithelial-to-mesenchymal transition. Nature, 2025. e-Pub 2025. PMID: 40044861.
- Colella, F, Calapà, F, Artemi, G, Pazzaglia, E, Colonna, R, Vitale, S, Lazzarino, G, Vincenzoni, F, Fiori, ME, De Maria, R, Lucchisani, S, Genovese, G, Perelli, L, Tavazzi, B, Sgambato, A, Lucchetti, D. CD147 Mediates the Metabolic Reprogramming of Cancer Associated Fibroblasts Induced by EVs Released by Differentiating Cancer Stem Cells. Journal of Extracellular Biology 4(3), 2025. e-Pub 2025.
- Colella F, Calapa F, Artemi G, Pazzaglia E, Colonna R, Vitale S, Lazzarino G, Vincenzoni F, Fiori ME, De Maria R, Lucchisani S, Genovese G, Perelli L, Tavazzi B, Sgambato A, Lucchetti D. CD147 Mediates the Metabolic Reprogramming of Cancer Associated Fibroblasts Induced by EVs Released by Differentiating Cancer Stem Cells. J Extracell Biol 4(3):e70039, 2025. e-Pub 2025. PMID: 40104175.
- Gubbiotti, M, McCutcheon, IE, Rao, P, Genovese, G, Wang, L, Tarasov, A, Putintsev, V, Berlinski, A, Stupichev, D, Kriukov, K, Davitavyan, S, Salem, B, Sarachakov, A, Lebedev, D, Hensley, M, Bagaev, A, Paradiso, F, Kushnarev, V, Khegai, G, Tannir, NM, Msaouel, P. A novel case of glial transdifferentiation in renal medullary carcinoma brain metastasis. Acta Neuropathologica Communications 13(1):12, 2025. e-Pub 2025. PMID: 39833894.
- Msaouel P, Yu K, Yuan Y, Chen J, Yan X, Karki M, Duan F, Sheth RA, Rao P, Sircar K, Shah AY, Zurita AJ, Genovese G, Li M, Yeh CC, Dang M, Han G, Chu Y, Hallin M, Olson P, Yang R, Slavin D, Der-Torossian H, Chin CD, Tannir NM, Wang L, Gao J. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial. Nat Commun 16(1):578, 2025. e-Pub 2025. PMID: 39794332.
- Esposito, A, Agostini, A, Quero, G, Piro, G, Priori, L, Caggiano, A, Scaglione, G, Battaglia, A, Calegari, MA, Salvatore, L, Bensi, M, Maratta, MG, Ceccarelli, A, Trovato, G, Genovese, G, Gurreri, E, Ascrizzi, S, Martini, M, Fiorillo, C, Fattorossi, A, De Sanctis, F, Ugel, S, Corbo, V, Alfieri, S, Tortora, G, Carbone, C. Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance. Cell Death and Disease 15(12), 2024. e-Pub 2024. PMID: 39632825.
- Perelli L, Genovese G, Draetta GF. The KRAS mutational spectrum and its clinical implications in pancreatic cancer. Cancer Cell 42(9):1494-1496, 2024. e-Pub 2024. PMID: 39214093.
- Bezwada D, Perelli L, Lesner NP, Cai L, Brooks B, Wu Z, Vu HS, Sondhi V, Cassidy DL, Kasitinon S, Kelekar S, Cai F, Aurora AB, Patrick M, Leach A, Ghandour R, Zhang Y, Do D, McDaniel P, Sudderth J, Dumesnil D, House S, Rosales T, Poole AM, Lotan Y, Woldu S, Bagrodia A, Meng X, Cadeddu JA, Mishra P, Garcia-Bermudez J, Pedrosa I, Kapur P, Courtney KD, Malloy CR, Genovese G, Margulis V, DeBerardinis RJ. Mitochondrial complex I promotes kidney cancer metastasis. Nature 633(8031):923-931, 2024. e-Pub 2024. PMID: 39143213.
- Ho IL, Li CY, Wang F, Zhao L, Liu J, Yen EY, Dyke CA, Shah R, Liu Z, Cetin AO, Chu Y, Citron F, Attanasio S, Corti D, Darbaniyan F, Del Poggetto E, Loponte S, Liu J, Soeung M, Chen Z, Jiang S, Jiang H, Inoue A, Gao S, Deem A, Feng N, Ying H, Kim M, Giuliani V, Genovese G, Zhang J, Futreal A, Maitra A, Heffernan T, Wang L, Do KA, Gargiulo G, Draetta G, Carugo A, Lin R, Viale A. Clonal dominance defines metastatic dissemination in pancreatic cancer. Sci Adv 10(11):eadd9342, 2024. e-Pub 2024. PMID: 38478609.
- Zussino M, Maronese CA, Montanelli G, Boggio FL, Moltrasio C, Cattaneo A, Marzano AV, Genovese G. Antinuclear matrix protein 2 antibody-positive dermatomyositis: a rare entity. Ital J Dermatol Venerol 159(1):76-78, 2024. e-Pub 2024. PMID: 38226939.
- Perelli L, Zhang L, Mangiameli S, Russell AJC, Giannese F, Peng F, Carbone F, Le C, Khan H, Citron F, Soeung M, Lam TNA, Lundgren S, Zhu C, Catania D, Feng N, Gurreri E, Sgambato A, Tortora G, Draetta GF, Tonon G, Futreal A, Giuliani V, Carugo A, Viale A, Heffernan TP, Wang L, Cittaro D, Chen F, Genovese G. Evolutionary fingerprints of EMT in pancreatic cancers. bioRxiv, 2023. e-Pub 2023. PMID: 37786705.
- Perelli L, Carbone F, Zhang L, Huang JK, Le C, Khan H, Citron F, Del Poggetto E, Gutschner T, Tomihara H, Soeung M, Minelli R, Srinivasan S, Peoples M, Lam TNA, Lundgren S, Xia R, Zhu C, Mohamed AMT, Zhang J, Sircar K, Sgambato A, Gao J, Jonasch E, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Signoretti S, Msaouel P, Litchfield K, Turajlic S, Wang L, Chen YB, Di Natale RG, Hakimi AA, Giuliani V, Heffernan TP, Viale A, Bristow CA, Tannir NM, Carugo A, Genovese G. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat Cancer 4(7):984-1000, 2023. e-Pub 2023. PMID: 37365326.
- Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G. SMARCB1 regulates the hypoxic stress response in sickle cell trait. Proc Natl Acad Sci U S A 120(21):e2209639120, 2023. e-Pub 2023. PMID: 37186844.
- Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, He R, Westerman ME, Gao J, Rao P, Lam TNA, Jonasch E, Perelli L, Cheng EH, Carugo A, Heffernan TP, Walker CL, Genovese G, Tannir NM, Karam JA, Msaouel P. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med 13(5):e1267, 2023. e-Pub 2023. PMID: 37226898.
- Chen Z, Ho IL, Soeung M, Yen EY, Liu J, Yan L, Rose JL, Srinivasan S, Jiang S, Edward Chang Q, Feng N, Gay JP, Wang Q, Wang J, Lorenzi PL, Veillon LJ, Wei B, Weinstein JN, Deem AK, Gao S, Genovese G, Viale A, Yao W, Lyssiotis CA, Marszalek JR, Draetta GF, Ying H. Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. Nat Commun 14(1):2194, 2023. e-Pub 2023. PMID: 37069167.
- Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol 6(2):228-232, 2023. e-Pub 2023. PMID: 34789422.
- Wu, C, Beird, H, Lamhamedi-Cherradi, SE, Soeung, M, Ingram, D, Truong, D, Porter, RW, Krishnan, S, Little, L, Gumbs, C, Zhang, J, Titus, M, Genovese, G, Ludwig, JA, Lazar, A, Hayes-Jordan, A, Futreal, A. Multi-site desmoplastic small round cell tumors are genetically related and immune-cold. npj Precision Oncology 6(1):21, 2022. e-Pub 2022. PMID: 35379887.
- Kaushik, AK, Tarangelo, A, Boroughs, LK, Ragavan, M, Zhang, Y, Wu, CY, Li, X, Ahumada, K, Chiang, JC, Tcheuyap, VT, Saatchi, F, Do, QN, Yong, C, Rosales, TI, Stevens, C, Rao, AD, Faubert, B, Pachnis, P, Zacharias, LG, Vu, H, Cai, F, Mathews, TP, Genovese, G, Slusher, BS, Kapur, P, Sun, X, Merrit, ME, Brugarolas, J, Deberardinis, RJ. In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. Science Advances 8(50), 2022. e-Pub 2022. PMID: 36525494.
- Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 33:100640, 2022. e-Pub 2022. PMID: 36174377.
- Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer 19(6):e401-e408, 2021. e-Pub 2021. PMID: 34625389.
- Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34885132.
- Puca F, Yu F, Bartolacci C, Pettazzoni P, Carugo A, Huang-Hobbs E, Liu J, Zanca C, Carbone F, Del Poggetto E, Gumin J, Dasgupta P, Seth S, Srinivasan S, Lang FF, Sulman EP, Lorenzi PL, Tan L, Shan M, Tolstyka ZP, Kachman M, Zhang L, Gao S, Deem AK, Genovese G, Scaglioni PP, Lyssiotis CA, Viale A, Draetta GF. Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. Cancer Discov 11(11):2904-2923, 2021. e-Pub 2021. PMID: 34039636.
- Del Poggetto E, Ho IL, Balestrieri C, Yen EY, Zhang S, Citron F, Shah R, Corti D, Diaferia GR, Li CY, Loponte S, Carbone F, Hayakawa Y, Valenti G, Jiang S, Sapio L, Jiang H, Dey P, Gao S, Deem AK, Rose-John S, Yao W, Ying H, Rhim AD, Genovese G, Heffernan TP, Maitra A, Wang TC, Wang L, Draetta GF, Carugo A, Natoli G, Viale A. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science 373(6561):eabj0486, 2021. e-Pub 2021. PMID: 34529467.
- Giuliani V, Miller MA, Liu CY, Hartono SR, Class CA, Bristow CA, Suzuki E, Sanz LA, Gao G, Gay JP, Feng N, Rose JL, Tomihara H, Daniele JR, Peoples MD, Bardenhagen JP, Geck Do MK, Chang QE, Vangamudi B, Vellano C, Ying H, Deem AK, Do KA, Genovese G, Marszalek JR, Kovacs JJ, Kim M, Fleming JB, Guccione E, Viale A, Maitra A, Emilia Di Francesco M, Yap TA, Jones P, Draetta G, Carugo A, Chedin F, Heffernan TP. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nat Commun 12(1):4626, 2021. e-Pub 2021. PMID: 34330913.
- Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology 161(1):196-210, 2021. e-Pub 2021. PMID: 33745946.
- Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33946504.
- Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant'Angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-Ivins M, Hirsch L, Baca SC, Wind-Rotolo M, Ross-Macdonald P, Sun M, Lee GM, Chang SL, Wei XX, McGregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, McDermott DF, Heng DYC, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun 12(1):808, 2021. e-Pub 2021. PMID: 33547292.
- Tomihara H, Carbone F, Perelli L, Huang JK, Soeung M, Rose JL, Robinson FS, Lissanu Deribe Y, Feng N, Takeda M, Inoue A, Poggetto ED, Deem AK, Maitra A, Msaouel P, Tannir NM, Draetta GF, Viale A, Heffernan TP, Bristow CA, Carugo A, Genovese G. Loss of ARID1A promotes epithelial-mesenchymal transition and sensitizes pancreatic tumors to proteotoxic stress. Cancer Res 81(2):332-343, 2021. e-Pub 2021. PMID: 33158812.
- Msaouel P, Genovese G, Gao J, Sen S, Tannir NM. TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?. Expert Opin Ther Targets:1-11. e-Pub 2020. PMID: 33356674.
- Citron F, Perelli L, Deem AK, Genovese G, Viale A. Leukotrienes, a potential target for Covid-19. Prostaglandins Leukot Essent Fatty Acids 161:102174, 2020. e-Pub 2020. PMID: 32977289.
- Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 37(5):720-734.e13, 2020. e-Pub 2020. PMID: 32359397.
- Dey P, Li J, Zhang J, Chaurasiya S, Strom A, Wang H, Liao WT, Cavallaro F, Denz P, Bernard V, Yen EY, Genovese G, Gulhati P, Liu J, Chakravarti D, Deng P, Zhang T, Carbone F, Chang Q, Ying H, Shang X, Spring DJ, Ghosh B, Putluri N, Maitra A, Wang YA, DePinho RA. Oncogenic Kras driven metabolic reprogramming in pancreas cancer cells utilizes cytokines from the tumor microenvironment. Cancer Discov. e-Pub 2020. PMID: 32046984.
- Adashek JJ, Genovese G, Tannir NM, Msaouel P. Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. Cancer Treat Res Commun 23:100166. e-Pub 2020. PMID: 31935623.
- Msaouel P, Walker CL, Genovese G, Tannir NM. Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye. Mol Cell Oncol 7(5):1777060, 2020. e-Pub 2020. PMID: 32944636.
- Msaouel P, Carugo A, Genovese G. Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?. Oncotarget 10(40):3979-3981, 2019. e-Pub 2019. PMID: 31258836.
- Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell 35(2):204-220.e9, 2019. e-Pub 2019. PMID: 30753823.
- Seth S, Li CY, Ho IL, Corti D, Loponte S, Sapio L, Del Poggetto E, Yen EY, Robinson FS, Peoples M, Karpinets T, Deem AK, Kumar T, Song X, Jiang S, Kang Y, Fleming J, Kim M, Zhang J, Maitra A, Heffernan TP, Giuliani V, Genovese G, Futreal A, Draetta GF, Carugo A, Viale A. Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. Cell Rep 26(6):1518-1532.e9, 2019. e-Pub 2019. PMID: 30726735.
- Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer 17(1):1-6, 2019. e-Pub 2019. PMID: 30287223.
- Lovisa S, Genovese G, Danese S. Role of epithelial-to-mesenchymal transition in inflammatory bowel disease. J Crohns Colitis. e-Pub 2018. PMID: 30520951.
- Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Atlas Network CG, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep 19(13):2878-2880, 2017. e-Pub 2017. PMID: 28658632.
- Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Atlas Network CG, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep 18(11):2780-2794, 2017. e-Pub 2017. PMID: 28297679.
- Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature 542(7641):362-366, 2017. e-Pub 2017. PMID: 28178232.
- Dey P, Baddour J, Muller F, Wu CC, Wang H, Liao WT, Lan Z, Chen A, Gutschner T, Kang Y, Fleming J, Satani N, Zhao D, Achreja A, Yang L, Lee J, Chang E, Genovese G, Viale A, Ying H, Draetta G, Maitra A, Wang YA, Nagrath D, DePinho RA. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature 542(7639):119-123, 2017. e-Pub 2017. PMID: 28099419.
- Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, Gupta S, Estecio MR, Giuliani V, Dellino GI, Riva L, Yao W, Di Francesco ME, Green T, D'Alesio C, Corti D, Kang Y, Jones P, Wang H, Fleming JB, Maitra A, Pelicci PG, Chin L, DePinho RA, Lanfrancone L, Heffernan TP, Draetta GF. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep 16(1):133-47, 2016. e-Pub 2016. PMID: 27320920.
- Gutschner T, Haemmerle M, Genovese G, Draetta GF, Chin L. Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair. Cell Rep 14(6):1555-66, 2016. e-Pub 2016. PMID: 26854237.
- Research Network CGA. Genomic Classification of Cutaneous Melanoma. Cell, 2015. e-Pub 2015.
- Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. Cancer Cell, 2015. e-Pub 2015. PMID: 25965571.
- Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, Kapoor A, Yao W, Francesco ME, Petrocchi A, Deem AK, Scott K, Colla S, Mills GB, Fleming JB, Heffernan TP, Jones P, Toniatti C, DePinho RA, Draetta GF. Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. Cancer Research, 2015. e-Pub 2015. PMID: 25736685.
- Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T, Genovese G, Wang G, Fang Z, Tepper JM, Stemke-Hale K, Tsai KY, Davies MA, Mills GB, Chin L. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res, 2014. e-Pub 2014. PMID: 25056119.
- Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming JB, Cantley LC, DePinho RA, Draetta GF. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature, 2014. e-Pub 2014. PMID: 25119024.
- Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, Network TR. The somatic genomic landscape of glioblastoma. Cell 155(2):462-77, 2013. e-Pub 2013. PMID: 24120142.
- Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18(10):1503-10, 2012. e-Pub 2012. PMID: 22983396.
- Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee MA, Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E, Ho D, Kwong L, Brennan C, Wang YA, Chin L, DePinho RA. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488(7411):337-42, 2012. e-Pub 2012. PMID: 22895339.
- Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, Kwong L, Dunn K, Wiedemeyer WR, Brennan C, Zheng H, Rimm DL, Collins JJ, Chin L. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov 2(8):736-49, 2012. e-Pub 2012. PMID: 22750848.
- Genovese G, Ghosh P, Li H, Rettino A, Sioletic S, Cittadini A, Sgambato A. The tumor suppressor HINT1 regulates MITF and β-catenin transcriptional activity in melanoma cells. Cell Cycle 11(11):2206-15, 2012. e-Pub 2012. PMID: 22647378.
- Einbond LS, Soffritti M, Degli Esposti D, Tibaldi E, Lauriola M, Bua L, He K, Genovese G, Su T, Huggins L, Wang X, Roller M, Wu HA. Chemopreventive potential of black cohosh on breast cancer in Sprague-Dawley rats. Anticancer Res 32(1):21-30, 2012. e-Pub 2012. PMID: 22213284.
- Coco C, Zannoni GF, Caredda E, Sioletic S, Boninsegna A, Migaldi M, Rizzo G, Bonetti LR, Genovese G, Stigliano E, Cittadini A, Sgambato A. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res 31:71, 2012. e-Pub 2012. PMID: 22964035.
- Sgambato A, Camerini A, Genovese G, De Luca F, Viacava P, Migaldi M, Boninsegna A, Cecchi M, Sepich CA, Rossi G, Arena V, Cittadini A, Amoroso D. Loss of nuclear p27(kip1) and α-dystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma. Cancer Sci 101(9):2080-6, 2010. e-Pub 2010. PMID: 20626751.
- Sgambato A, Puglisi MA, Errico F, Rafanelli F, Boninsegna A, Rettino A, Genovese G, Coco C, Gasbarrini A, Cittadini A. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection. J Cell Physiol, 2010. e-Pub 2010. PMID: 20333645.
- Rettino A, Rafanelli F, Genovese G, Goracci M, Cifarelli RA, Cittadini A, Sgambato A. Identification of Sp1 and GC-boxes as transcriptional regulators of mouse Dag1 gene promoter. Am J Physiol Cell Physiol 297(5):C1113-23, 2009. e-Pub 2009. PMID: 19657058.
- Einbond LS, Shimizu M, Ma H, Wu HA, Goldsberry S, Sicular S, Panjikaran M, Genovese G, Cruz E. Actein inhibits the Na+-K+-ATPase and enhances the growth inhibitory effect of digitoxin on human breast cancer cells. Biochem Biophys Res Commun 375(4):608-13, 2008. e-Pub 2008. PMID: 18755149.
- Sgambato A, Camerini A, Amoroso D, Genovese G, De Luca F, Cecchi M, Migaldi M, Rettino A, Valsuani C, Tartarelli G, Donati S, Siclari O, Rossi G, Cittadini A. Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma. Cancer Biol Ther 6(12):1840-6, 2007. e-Pub 2007. PMID: 18087214.
Other Articles
- Msaouel P, Genovese G, Tannir NM Renal Cell Carcinoma of Variant Histology: Biology and Therapies. Hematol Oncol Clin North Am 37(5):977-992, 2023. PMID: 37244822.
- Gurreri E, Genovese G, Perelli L, Agostini A, Piro G, Carbone C, Tortora G KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy. Int J Mol Sci 24(11), 2023. PMID: 37298264.
- Sarkar S, Throckmorton W, Bingham R, Msaouel P, Genovese G, Slopis J, Rao P, Sadighi Z, Herzog CE Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2. Curr Oncol 30(3):3355-3365, 2023. PMID: 36975468.
- Zoumpourlis P, Genovese G, Tannir NM, Msaouel P Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. Clin Genitourin Cancer 19(2):103-116, 2021. PMID: 33358151.
- Adashek JJ, Leonard A, Roszik J, Menta AK, Genovese G, Subbiah V, Msaouel P Cancer Genetics and Therapeutic Opportunities in Urologic Practice. Cancers (Basel) 12(3), 2020. PMID: 32197306.
- Muller F, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee M, Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E, Ho D, Kwong L, Brennan C, Wang YA, Chin L, DePinho RA Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 525(7568):278, 2015. PMID: 26153864.
- Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26(8):756-84, 2012. PMID: 22508724.
Selected Presentations & Talks
National Presentations
- 2022. Cancer Models, US.
- 2021. Kidney Cancer Research Summit. Kidney Cancer Research Summit, US.
Formal Peers
- 2021. Modeling Renal Cancer Evolution. Invited. Modeling Renal Cancer Evolution, US.
- 2020. Modeling Renal Cancer Evolution. Invited. Modeling Renal Cancer Evolution, US.
- 2017. Cell Plasticity in Pancreatic Cancer. Invited. Cell Plasticity in Pancreatic Cancer, US.
- 2017. Epigenetic Regulation of Pancreatic Cancer Progression. Invited. Epigenetic Regulation of Pancreatic Cancer Progression, US.
- 2017. Epigenetic Regulation of Pancreatic Cancer Progression. Invited. Epigenetic Regulation of Pancreatic Cancer Progression, US.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Functional and clonal characterization of the paradoxical extinction of KRAS signaling in pancreatic cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA295881-01A1 |
| Date: | 2025 - 2029 |
| Title: | Functional and Clonal Characterization of the Extinction of HIF Signaling in VHL-Driven Renal Cancers |
| Funding Source: | DOD |
| Role: | PI |
| ID: | PR240492 |
| Date: | 2025 - 2030 |
| Title: | Project 1: Define the oncogenic and immunologic effects of 9p21 loss in cancers |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | P01 CA288293-01 |
| Date: | 2025 - 2026 |
| Title: | Cryogen-Free Preclinical 7T MRI Scanner |
| Funding Source: | NIH/OD |
| Role: | PI |
| ID: | 1S10 |
| Date: | 2024 - 2027 |
| Title: | Targeting Myeloid Mimicry in Renal Medullary Carcinoma |
| Funding Source: | DOD |
| Role: | Co-I |
| ID: | RA230062 |
| Date: | 2024 - 2029 |
| Title: | Functional and clonal characterization of the paradoxical extinction of KRAS signaling in pancreatic cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA295881-01 |
| Date: | 2024 - 2029 |
| Title: | Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic Alleviation |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA285454-01A1 |
| Date: | 2024 - 2029 |
| Title: | Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies |
| Funding Source: | NIH/NCI |
| Role: | Consult |
| ID: | R37 CA288448-01 |
| Date: | 2021 - 2024 |
| Title: | Targeting resistance mechanisms in SMARCB1-deficient tumors |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | KC200096 |
| Date: | 2021 - 2026 |
| Title: | Effective Combination Therapy for MTAP-Deficient Bladder Carcinoma by Targeting Metabolic Vulnerability and modulating Tumor Immune Microenvironment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA254988-01A1 |
| Date: | 2021 - 2026 |
| Title: | Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1 R01 CA258886-01 |
| Date: | 2021 - 2026 |
| Title: | Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma |
| Funding Source: | NIH |
| Role: | PI |
| ID: | 1 R01 CA258226-01 |
| Date: | 2021 - 2023 |
| Title: | Investigation of the Role of Epithelial-Mesenchymal Plasticity in Pancreatic Cancer Evolution |
| Funding Source: | The Andrew Sabin Family Foundation |
| Role: | Co-I |
| ID: | RO1 CA258226-04 |
| Date: | 2021 - 2023 |
| Title: | Clonal Drivers of Resistance to Immune Checkpoint Blockade In Liver Malignancies |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21 CA259799-02 |
| Date: | 2019 - 2021 |
| Title: | Clonal drivers of resistance to immune checkpoint blockade in Renal Cell Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21 CA259799 A01 |
| Date: | 2019 - 2024 |
| Title: | Next-Generation Targeting of Chromatin Remodeler Defects in Renal Cell Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA237910 |
| Date: | 2018 - 2020 |
| Title: | A Novel Mechanism of Pathogenesis for Renal Medullary Carcinoma |
| Funding Source: | DOD KCRP Concept Award |
| Role: | Co-I |
| ID: | W81XHW-18-1-0570 |
| Date: | 2018 - 2021 |
| Title: | Cell Plasticity and Mesenchymal Reprogramming in Kidney Cancer Progression |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | PI |
| Date: | 2018 - 2023 |
| Title: | Mesenchymal reprogramming in pancreatic cancer cells |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1-R01-CA226294-01 |
| Date: | 2018 - 2021 |
| Title: | Initiative for Genetically Engineered Mouse Models (GEMM) in Genitourinary Cancers |
| Funding Source: | MD Anderson's Prostate Cancer Research Program |
| Role: | Co-PI |
| Date: | 2017 - 2020 |
| Title: | Identification of critical dependencies and actionable therapeutic options in Smarcb1- deficient pediatric tumors |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP170722 |
| Date: | 2017 - 2019 |
| Title: | Therapeutic vulnerabilities of mesenchymal pancreatic cancer cells |
| Funding Source: | Pancreatic Cancer Action Network |
| Role: | Co-I |
| ID: | 17-65-DRAE |
| Date: | 2012 - 2017 |
| Title: | Biological Annotation of TCGA Data |
| Funding Source: | NIH/NCI |
| Role: | Key |
| ID: | U01 CA168394 |
| Date: | 2011 - 2018 |
| Title: | The Nexus of Epigenetics and Immune-oncology: Translational Research to Develop Combined Therapies |
| Funding Source: | Department of Defense (DOD) |
| Role: | Collaborator |
| ID: | W81XWH-11-1-0418 |
CV information above last modified April 28, 2025
Request an Appointment
Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
Related Links
Clinical Trials
Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.